ASH 2020 | GRIFFIN: follow-up after DARA + RVd for multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses updated safety and efficacy results from the Phase II GRIFFIN study (NCT02874742) of daratumumab (DARA) plus lenalidomide, bortezomib and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma. The study found that after a median 26.7 months of follow-up the addition of DARA to RVd induction and consolidation therapy followed by DARA plus lenalidomide maintenance therapy demonstrated deep and improved responses, including higher rates of minimal residual disease negativity compared to lenalidomide maintenance therapy alone. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
